Avacopan‐Associated Hepatobiliary Adverse Events and Vanishing Bile Duct Syndrome: A PMDA/JADER and FAERS Reporting‐Profile Comparison
Hepatology Research · 2026-11 · 56 (11) · 1754-1760
DOI: 10.1111/hepr.70242 ↗Abstract
ABSTRACT Aim Avacopan is an oral C5a receptor antagonist approved for anti‐neutrophil cytoplasmic antibody‐associated vasculitis. Recent post‐marketing safety information has raised concern regarding serious hepatobiliary injury, including vanishing bile duct syndrome (VBDS). We compared Japanese and FAERS post‐marketing reporting profiles for avacopan‐associated adverse events. Methods FAERS public dashboard data and PMDA CSV data downloaded in May 2026 were searched using Japanese and English avacopan/Tavneos terms and analyzed at the case report and adverse‐event/preferred‐term row levels. FAERS Public Dashboard aggregate data were searched using the avacopan generic‐name listing as the primary definition and the Tavneos product‐name listing as a sensitivity definition. Results PMDA/JADER contained 397 avacopan‐related reports and 744 adverse‐event/preferred‐term rows. FAERS contained 5770 reports in the avacopan generic‐name listing and 5216 reports in the Tavneos product‐name listing. Hepatobiliary preferred terms were prominent in PMDA/JADER, including hepatic function abnormal ( n = 86), liver disorder ( n = 44), drug‐induced liver injury ( n = 40), and VBDS ( n = 29). Among PMDA/JADER VBDS reports with available dates, the median time to onset was 44.0 days (interquartile range, 39.5–52.0). Conclusions Post‐marketing reports of avacopan‐associated hepatobiliary injury, including VBDS, warrant clinical attention, particularly during the early treatment period. PMDA/JADER and FAERS findings should be interpreted as differences in reporting profiles rather than direct comparisons of incidence or risk.
EUVIMED